# Efficacy and Safety of ES16001 in Patients With COVID-19

> **NCT05525182** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Genencell Co. Ltd.** · enrollment: 706 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** ES16001 40 mg
- **DRUG:** ES16001 80 mg
- **DRUG:** ES16001 160 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05525182
- **Lead sponsor:** Genencell Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-05
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 706 (ESTIMATED)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525182, "Efficacy and Safety of ES16001 in Patients With COVID-19". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05525182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*